The prevalence of inflammatory bowel disease (IBD) among adults seems to be increasing significantly, yet there are signs that the utilization of biologics to treat patients with this chronic disease have plateaued.
The prevalence of inflammatory bowel disease (IBD) among adults seems to be increasing significantly, yet there are signs that the utilization of biologics to treat patients with this chronic disease have plateaued.
In the October 28, 2016 issue of Mortality Morbidity Weekly Review, researchers from the Centers for Disease Control and Prevention (CDC) announced the findings of its 2015 National Health Interview Survey on IBD. They estimated that the prevalence of IBD in the US adult population was 3.1 million (1.3% of the total US adult population). A similar study conducted in 1999 found the figure to be 1.8 million (or 0.9% of the adult US population), a 72% increase in number and a 44% increase by proportion of the population. According to the CDC, a dominating factor in this trend is a substantially higher prevalence of IBD identified among adults aged ≥45 years, mostly in Hispanics and non-Hispanic whites, and those in lower socioeconomic levels. The NHIS is based on the survey responses of more than 33,500 American adults.
This raises the question of whether the utilization of biologics used to treat IBD has also increased over this time. Remicade® was approved for use in 1998, and Humira® was approved in 2002 (the anti-TNF fusion protein etanercept was also approved in 1998, but is not indicated for IBD). These remain the two most commonly used agents to treat IBD, especially Crohn’s disease, with Cimzia® a distant third. Based on a single-center study from Stanford University, the utilization of biologics for adults and children with IBD has not increased proportionately. Use of Remicade® peaked in 2008, and utilization of Humira continued somewhat slow growth through 2012, the end of the data collection period. Interestingly, biologic use in IBD resulted in dramatic lowering of hospitalization costs, but not in the rate of abdominal surgery in these patients. They attribute this finding to the possible erosion of drug efficacy when given chronically over the long term. However, the Stanford researchers also found that pharmaceutical therapy in IBD, particularly Crohn’s disease, is the primary cost component in health care expenditures. “Pharmacy utilization costs account for nearly one-half (45.5%) of the total CD-attributable costs, exceeding inpatient care costs. Anti-TNF agents alone comprised nearly one-third (29.5%) of total costs,” they said.
The question of whether the biologic utilization pie is growing, shrinking, or remaining the same could have implications for the brand new biosimilar market for IBD.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.